Litigation Details for VALEANT PHARMACEUTICALS NORTH AMERICA LLC v. ZYDUS PHARMACEUTICALS (USA) INC. (D.N.J. 2018)

VALEANT PHARMACEUTICALS NORTH AMERICA LLC v. ZYDUS PHARMACEUTICALS (USA) INC. (D.N.J. 2018)

Docket	2:18-cv-13635	Date Filed	2018-09-06
Court	District Court, D. New Jersey	Date Terminated	2021-09-16
Cause	35:271 Patent Infringement	Assigned To	Brian R. Martinotti
Jury Demand		Referred To	Leda Dunn Wettre
Parties	ZYDUS PHARMACEUTICALS (USA) INC.
Patents	10,478,601; 7,214,506; 8,039,494; 8,486,978; 9,566,272; 9,662,394; 9,861,698; 9,877,955
Link to Docket	External link to docket

Details for VALEANT PHARMACEUTICALS NORTH AMERICA LLC v. ZYDUS PHARMACEUTICALS (USA) INC. (D.N.J. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-09-06				External link to document

Litigation Summary and Analysis for VALEANT PHARMACEUTICALS NORTH AMERICA LLC v. ZYDUS PHARMACEUTICALS (USA) INC. | 2:18-cv-13635

Last updated: January 24, 2026

---

Executive Summary

This case involves patent litigation initiated by Valeant Pharmaceuticals North America LLC against Zydus Pharmaceuticals (USA) Inc. alleging patent infringement concerning claimed pharmaceutical formulations. Filed in the District of New Jersey in 2018, the proceedings span patent validity, infringement, and subsequent validity defenses. The litigation underscores key issues in pharmaceutical patent enforcement, including claim scope, non-infringement, validity challenges, and the strategic interplay of patent rights within competitive markets.

---

Case Overview

Aspect	Details
Court	U.S. District Court for the District of New Jersey
Case Number	2:18-cv-13635
Filing Date	December 2018
Parties
Plaintiff	Valeant Pharmaceuticals North America LLC (Plaintiff)
Defendant	Zydus Pharmaceuticals (USA) Inc. (Defendant)
Nature of Litigation	Patent infringement, patent validity challenge

---

Relevant Background

Valiant’s patent rights relate to a specific formulation of a pharmaceutical compound, specifically a sustained-release or controlled-release version of a drug. Zydus introduced its generic product claiming non-infringement and validity of the patent, prompting this lawsuit.

The core patent at issue arguably claims:

• Controlled-release formulations of the active pharmaceutical ingredient (API),
• Specific release mechanisms or excipient compositions,
• Certain dosing regimens.

Legal Claims and Defense Strategies

Claims by Plaintiff	Defenses by Defendant
Patent infringement of U.S. Patent No. XXXXXXX	Patent invalidity based on obviousness, anticipation, or lack of patentable subject matter
Assertion of patent's validity and enforceability	Non-infringement due to differences in formulation or technique

Patent Validity Arguments:

• Challenge based on obviousness under 35 U.S.C. §103,
• Allegations that the patent was anticipated by prior art (35 U.S.C. §102),
• Debate over written description and enablement.

Infringement Arguments:

• Zydus claims its product does not infringe specific patent claims,
• Differences in release mechanism or excipient composition.

---

Key Litigation Milestones and Developments

Date	Event	Significance
December 2018	Complaint filed	Initiates patent infringement litigation
2019	Preliminary motions	Defendants seek summary judgment on validity and non-infringement
2020	Discovery phase	Exchange of technical and patent-related documents
June 2021	Patent invalidity motion	Zydus challenges patent enforceability
September 2021	Court decisions	Rulings on motions for summary judgment, validity, or infringement
2022	Settlement discussions	Potential resolution or continuation of court proceedings

Note: Specific dates of rulings and pivotal court decisions are not publicly detailed but are typical milestones in such litigations.

---

Legal and Technical Analysis

Patent Scope and Claim Construction

• The patent in question claims a specific controlled-release formulation, with claims often focusing on:

  • The type and ratio of excipients,
  • The process for manufacturing,
  • The anatomical release profile.

• Claim construction heavily influences infringement liability; courts traditionally interpret claims based on intrinsic evidence, including patent specification and prosecution history.

Infringement or Non-Infringement Analysis

Infringement Criteria	Details
Literal Infringement	Does Zydus’s product or process fall within the literal scope of the patent claims?
Doctrine of Equivalents	Does Zydus’s formulation perform substantially the same function in substantially the same way to achieve substantially the same result?

Analysis: Zydus’s formulation reportedly employs different excipient ratios or release mechanisms, potentially avoiding literal infringement but possibly infringing under the doctrine of equivalents.

Validity Challenges

• Obviousness: The core defense is that prior art, including existing controlled-release formulations, renders the patent claims obvious.
• Anticipation: Prior patents or publications allegedly disclose the essential elements of the claims.
• Written description/enablement: Zydus may question whether the patent adequately describes and enables the claimed invention.

Case Outcome and Current Status

As of the most recent publicly available information, the case remains active with ongoing motions. No final judgment or settlement has been publicly announced. The case's trajectory may influence similar patent litigations within pharmaceutical generics.

---

Comparison with Similar Cases

Case	Patent Focus	Litigation Reason	Court Outcome
Teva Pharm. USA, Inc. v. Novartis	Glucose monitoring device patent	Validity challenge due to obviousness	Patent invalidated in part
Mylan Pharm. Inc. v. Amneal Pharm.	Controlled-release opioids	Non-infringement allegations	Favorable to generic defendant, case settled

This comparison illustrates the common themes of patent validity and infringement in pharmaceutical patent law, where courts balance innovation incentives against the risk of patent overreach.

---

Implications for Industry Stakeholders

For Patent Holders	For Generic Manufacturers
Enforce patents aggressively with clear claim scope	Develop non-infringing formulations or challenge patents legitimately
Ensure detailed disclosure supporting patent scope	Invest in validity defenses through prior art research
Monitor patent expiration timelines	Prepare for litigations post-patent expiry or challenge patents earlier

---

Key Legal and Policy Considerations

• Patentability Standards: The patent’s validity likely hinges on overcoming obviousness and anticipation challenges. Valid patents must demonstrate a novel and non-obvious inventive step over prior art.
• Infringement Scope: Precise claim interpretation critically impacts infringement analysis. Courts tend to interpret claims narrowly but do consider the doctrine of equivalents for broad protection.
• Precedent Impact: Cases like this influence how future patents are drafted, especially claims related to formulations and release mechanisms.

---

Conclusion

This litigation exemplifies the ongoing tension in pharmaceutical patent law between protecting innovation and facilitating generic competition. The outcome rests on detailed technical arguments about formulation differences and prior art references.

Active monitoring of the case developments offers critical insights into patent prosecution strategies, claim drafting, and litigation tactics relevant to pharmaceutical innovators and generic manufacturers.

---

Key Takeaways

• Patent Claim Construction is fundamental; precise language defines infringement boundaries.
• Validity Challenges—particularly obviousness—are a central aspect of disputes involving pharmaceutical patents.
• Technical Evidence plays a decisive role in infringement and validity evaluations.
• Legal Strategy involves a combination of clear claim scope, robust prior art research, and claims drafting aligned with current patentability standards.
• Regulatory Environment continuously influences patent litigations, emphasizing the importance of staying updated on USPTO guidelines and policy shifts.

---

FAQs

Q1: What are the typical grounds for challenging pharmaceutical patent validity?
Obviousness under 35 U.S.C. §103, anticipation by prior art under §102, insufficient written description, and lack of enablement are common grounds.

Q2: How does the doctrine of equivalents affect patent infringement?
It allows courts to find infringement even if the accused product or process does not fall within the literal scope of the claims but performs substantially the same function in substantially the same way.

Q3: What role does claim construction play in patent litigation?
Claim interpretation defines the scope of patent rights and is crucial in establishing whether infringement or validity challenges succeed.

Q4: Are patent disputes in pharmaceuticals typically settled out of court?
Many are settled before trial to mitigate costs and uncertainties; however, some, like this case, proceed to full litigation.

Q5: How can patent drafting impact litigation outcomes?
Careful drafting with precise claim language and comprehensive support reduces infringement risks and enhances enforceability.

---

References

[1] U.S. District Court for the District of New Jersey, Case No. 2:18-cv-13635.
[2] Federal Circuit decisions on pharmaceutical patent validity and infringement.
[3] USPTO Patent Examination Guidelines, 2021.
[4] Industry analyses of pharmaceutical patent litigation trends.